[
  {
    "ts": null,
    "headline": "Gilead appoints Sanofi official Dietmar Berger as next chief medical officer",
    "summary": "Berger, who will join on Jan. 2, was most recently French pharmaceutical giant Sanofi's chief medical officer.  At the french drugmaker, he was also the global head of development, where he led development science, strategy and operations across the company's therapeutic areas of focus.",
    "url": "https://finnhub.io/api/news?id=863a24f3f2109780222c86e9cdb051aebc5c73733287ff397fdf95a74c169ca0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734044077,
      "headline": "Gilead appoints Sanofi official Dietmar Berger as next chief medical officer",
      "id": 131952211,
      "image": "https://media.zenfs.com/en/reuters-finance.com/ecc550f17ca0762c34374ea32ea2f964",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Berger, who will join on Jan. 2, was most recently French pharmaceutical giant Sanofi's chief medical officer.  At the french drugmaker, he was also the global head of development, where he led development science, strategy and operations across the company's therapeutic areas of focus.",
      "url": "https://finnhub.io/api/news?id=863a24f3f2109780222c86e9cdb051aebc5c73733287ff397fdf95a74c169ca0"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer",
    "summary": "FOSTER CITY, Calif., December 12, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD.",
    "url": "https://finnhub.io/api/news?id=3dc277371522d7c63dd2ce8fa70da1daf6a22ecf554cc3068224036b67706305",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734042600,
      "headline": "Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer",
      "id": 131966494,
      "image": "https://s.yimg.com/ny/api/res/1.2/Pd0o1aq83MSRu.JrNzrFWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/fac28b26fb8492072db76e4131ff167d",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., December 12, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD.",
      "url": "https://finnhub.io/api/news?id=3dc277371522d7c63dd2ce8fa70da1daf6a22ecf554cc3068224036b67706305"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing",
    "summary": "At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a once-yearly injectable formulation for lenacapavir. The annual formulation is currently in Phase 1 study, with data to be presented. In its investor presentation, the company said it expects the pivotal Phase 3 pharmacokinetics study’s first patient to be in 2025, and potential regulatory filings will begin in late 2027. In September, Gilead revealed the results of an interim analy",
    "url": "https://finnhub.io/api/news?id=d363d88898bbfc4e4371c9db0e7c33dbcc210ae83d6903dd0b659516e313b6f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734027205,
      "headline": "Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing",
      "id": 131966495,
      "image": "https://media.zenfs.com/en/Benzinga/1f627be299bbbea80202e4bf0d273b5d",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a once-yearly injectable formulation for lenacapavir. The annual formulation is currently in Phase 1 study, with data to be presented. In its investor presentation, the company said it expects the pivotal Phase 3 pharmacokinetics study’s first patient to be in 2025, and potential regulatory filings will begin in late 2027. In September, Gilead revealed the results of an interim analy",
      "url": "https://finnhub.io/api/news?id=d363d88898bbfc4e4371c9db0e7c33dbcc210ae83d6903dd0b659516e313b6f7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer",
    "summary": "By Paul Ziobro Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. Berger had held the same role at Sanofi,...",
    "url": "https://finnhub.io/api/news?id=89bafd09ee435d3cb703bd3e1ccc18e8117d8a48628bd5303547ab0cd4c9a930",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734027188,
      "headline": "Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer",
      "id": 131954037,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "By Paul Ziobro Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. Berger had held the same role at Sanofi,...",
      "url": "https://finnhub.io/api/news?id=89bafd09ee435d3cb703bd3e1ccc18e8117d8a48628bd5303547ab0cd4c9a930"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead Sciences (GILD) Stock Undervalued Right Now?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=c7b2442c7e2709015804b2a2e456219952974f3db5d3eb5012da10ab110f0b70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734014412,
      "headline": "Is Gilead Sciences (GILD) Stock Undervalued Right Now?",
      "id": 131931259,
      "image": "https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=c7b2442c7e2709015804b2a2e456219952974f3db5d3eb5012da10ab110f0b70"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=c99b97cba764e2d0cf97a827ba361aac1d9c6bfda4655807ca3d2138ac9930ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734012014,
      "headline": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 131931260,
      "image": "https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=c99b97cba764e2d0cf97a827ba361aac1d9c6bfda4655807ca3d2138ac9930ad"
    }
  },
  {
    "ts": null,
    "headline": "Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. IDACORP, Gilead Sciences and Fifth Third Bancorp have rewarded shareholders for decades and recently announced dividend ...",
    "url": "https://finnhub.io/api/news?id=8d0f23531560a5850da3eadc8fd738245e7a85d181d2eab4b3895526b7495c97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734004814,
      "headline": "Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers",
      "id": 131929253,
      "image": "https://media.zenfs.com/en/benzinga_79/716fc2a74884f8d0a07dbf4fb38b4735",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. IDACORP, Gilead Sciences and Fifth Third Bancorp have rewarded shareholders for decades and recently announced dividend ...",
      "url": "https://finnhub.io/api/news?id=8d0f23531560a5850da3eadc8fd738245e7a85d181d2eab4b3895526b7495c97"
    }
  },
  {
    "ts": null,
    "headline": "Unsupported price hikes added $815 million to US drug spending in 2023",
    "summary": "Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an...",
    "url": "https://finnhub.io/api/news?id=3ab0b35e7ef7672cb0f95df2b96cf147210a70e376bd5a1eaea056dadabb3c96",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733990602,
      "headline": "Unsupported price hikes added $815 million to US drug spending in 2023",
      "id": 131927943,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an...",
      "url": "https://finnhub.io/api/news?id=3ab0b35e7ef7672cb0f95df2b96cf147210a70e376bd5a1eaea056dadabb3c96"
    }
  }
]